share_log

Benchmark Upgrades Emergent BioSolutions to Buy, Announces $22 Price Target

Benzinga ·  Apr 10, 2023 19:00

Benchmark analyst Robert Wasserman upgrades Emergent BioSolutions (NYSE:EBS) from Hold to Buy and announces $22 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment